08:25 AM EDT, 08/04/2025 (MT Newswires) -- Cassava Sciences ( SAVA ) said Monday that simufilam reduced seizure frequency in a mouse model of tuberous sclerosis complex-related epilepsy.

The company said the mice were treated with multiple doses of simufilam and seizure activity was monitored for three weeks.

According to the company, the drug candidate attenuated the progression of seizure activity with a statistically significant correlation between simufilam dose and the number of seizures.

A first clinical study is expected to begin in H1 2026, the company said.

Shares of Cassava Sciences ( SAVA ) rose more than 3% in recent premarket activity Monday.

Price: 2.20, Change: +0.08, Percent Change: +3.78